Sugi Predict

Sugi Predict / Compounds / SCHEMBL4473867

SCHEMBL4473867

SCHEMBL4473867

Nc1nc(Nc2ccc(Oc3ccccc3)cc2)sc1C(=O)c1ccccc1Cl

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.76
▸ TP53 P04637 2/20 0.76
▸ RXFP1 Q9HBX9 1/20 0.76
▸ CDK4 P11802 2/20 0.63
▸ CCND1 P24385 2/20 0.63
▸ CDK9 P50750 2/20 0.63
▸ CDK6 Q00534 2/20 0.63
▸ CCNT1 O60563 1/20 0.63
▸ CDK11A Q9UQ88 1/20 0.63
▸ CDK5 Q00535 6/20 0.58
▸ CDK5R1 Q15078 6/20 0.58
▸ MEN1 O00255 3/20 0.58
▸ KMT2A Q03164 3/20 0.58
▸ LMNA P02545 1/20 0.58
▸ CCNA2 P20248 8/20 0.57
▸ CDK2 P24941 8/20 0.57
▸ NPC1 O15118 3/20 0.57
▸ GSK3B P49841 3/20 0.57
▸ MAPK14 Q16539 2/20 0.57
▸ GSK3A P49840 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4486578 0.85 CCNA2 (0.79) MAPTCDK4CCND1CDK9CDK6
SCHEMBL4471081 0.85 CDK5 (0.78) MAPTCDK5CDK5R1MEN1KMT2A
SCHEMBL4465180 0.82 CCNA2 (0.82) MAPTTP53CDK5CDK5R1MEN1
SCHEMBL4473974 0.81 CDK5 (0.87) MAPTCDK4CCND1CDK9CDK6
SCHEMBL25609769 0.80 CCNA2 (0.81) MAPTTP53CDK5CDK5R1MEN1
SCHEMBL4481111 0.80 GSK3B (0.80) MAPTTP53RXFP1CDK4CCND1
SCHEMBL4473183 0.79 CCNA2 (0.88) MAPTTP53CDK4CCND1CDK5
SCHEMBL4487774 0.79 CDK5 (0.68) MAPTCDK5CDK5R1MEN1KMT2A
SCHEMBL4391380 0.79 CCNA2 (0.70) MAPTTP53RXFP1CDK4CCND1
SCHEMBL4473028 0.78 GSK3B (0.73) MAPTTP53RXFP1CDK4CCND1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8470821-B2 PDE4B inhibitors and uses therefor PLEXXIKON INC. (US) 2013-06-25 — — US disclosed
US-8470821-B2 PDE4B inhibitors and uses therefor PLEXXIKON INC. (US) 2013-06-25 — — US disclosed
US-8470821-B2 PDE4B inhibitors and uses therefor PLEXXIKON INC. (US) 2013-06-25 — — US disclosed
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PLEXXIKON, INC. 2009-11-19 — — US disclosed
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PLEXXIKON, INC. 2009-11-19 — — US disclosed
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PLEXXIKON, INC. 2009-11-19 — — US disclosed
US-7585859-B2 PDE4B inhibitors and uses therefor PLEXXIKON, INC. (US) 2009-09-08 — — US disclosed
US-7585859-B2 PDE4B inhibitors and uses therefor PLEXXIKON, INC. (US) 2009-09-08 — — US disclosed
US-7585859-B2 PDE4B inhibitors and uses therefor PLEXXIKON, INC. (US) 2009-09-08 — — US disclosed
US-20060041006-A1 PDE4B inhibitors and uses therefor PLEXXIKON, INC. 2006-02-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PDE4B, PDE7B, PDE4A MAPT 3524/4885TP53 4190/4885RXFP1 582/4885
US-20060041006-A1 PDE4B inhibitors and uses therefor PDE4B, PDE7B, PDE4A MAPT 3524/4885TP53 4190/4885RXFP1 582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.